论文部分内容阅读
据报道，GeneticsInstitute公司和WyethAyerst公司的重组人白细胞介素-11（rhIL－11）能明显减少用环磷酸肢和多柔比星进行高剂量化疗的女性对输往血小板的需求。研究者指出，采用rhIL．11减轻血小板的减少，可使拟定的化疗方案维持几个疗程，从而避免减少剂量对治疗结果的负面
Genetics Institute and WyethAyerst’s recombinant human interleukin-11 (rhIL-11) was reported to significantly reduce the need for platelet delivery in women receiving high-dose chemotherapy with cyclophospholipids and doxorubicin. The researchers pointed out that using rhIL. 11 Reducing the reduction of platelets can allow the planned chemotherapy regimen to be maintained for several courses, so as to avoid reducing the negative effect of the dose on the treatment outcome.